SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEOPRNewsWire • 05/17/24
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate ProgressGlobeNewsWire • 05/15/24
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 05/07/24
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 05/03/24
Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRLSeeking Alpha • 05/02/24
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of InvestorsBusiness Wire • 05/02/24
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of InvestorsBusiness Wire • 05/02/24
The Law Offices of Frank R. Cruz Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of InvestorsBusiness Wire • 04/29/24
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA InspectionsGlobeNewsWire • 03/18/24
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)GlobeNewsWire • 02/01/24
Abeona Therapeutics stock climbs after drug candidate receives FDA Priority ReviewProactive Investors • 11/27/23
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)GlobeNewsWire • 11/27/23
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate DevelopmentsGlobeNewsWire • 11/13/23
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis BullosaGlobeNewsWire • 09/26/23
Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial OfficerGlobeNewsWire • 09/12/23
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA SubmissionGlobeNewsWire • 08/30/23